Parabilis Medicines, Inc. (PBLS) Stock Price & Analysis

36 Followers

PBLS Stock Chart & Stats

$29.65-$0.37(-1.23%)

At close: Nov 11 4:00 PM EST

Day’s Range: $29.29 - $30.98
52-Week Range: $22.66 - $42.49
Previous Close: $30.02
Volume: N/A
Average Volume (3M): 1.05M
Market Cap: $3.71B
Enterprise Value: $2.31B
Total Cash (Recent Filing): $1.12B
Total Debt (Recent Filing): $47.51M
Price to Earnings (P/E): ―
Beta: -0.44
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Debt Reduction

Lower total debt provides a modest improvement in the capital structure and reduces the absolute burden of borrowings. Although negative equity and cash burn remain serious concerns, this reduction offers slightly more financial flexibility than a balance sheet with rising debt.

Development-Stage Biotech Profile

The pre-revenue profile is consistent with a development-stage biotechnology business, where investment may precede commercialization. This does not resolve the funding risk, but it indicates that current losses could reflect the timing of product development rather than a mature operation with declining sales.

Reported Workforce

A reported workforce of 145 people represents an established personnel base relative to the company’s pre-revenue stage. Maintaining this scale may support ongoing scientific, clinical, and corporate activities, although the pack does not provide evidence that it has yet produced commercial revenue.

Bears Say

No Revenue

No reported revenue means the company lacks an established commercial funding engine and must rely on financing or other capital sources to support its activities. This weakens earnings visibility and leaves future financial performance dependent on successful commercialization that has not yet occurred.

Widening Losses

The widening net loss shows that profitability deteriorated even though the company remained pre-revenue. Persistent and expanding losses increase the amount of capital required before potential commercialization, reducing financial resilience and making future operating performance more difficult to sustain.

Cash Burn And Negative Equity

Heavy operating cash burn indicates that reported losses are translating into substantial cash outflows, while negative equity signals accumulated balance-sheet strain. Together, these conditions increase dependence on external funding and raise the risk of dilution or restricted financial flexibility.

Parabilis Medicines, Inc. News

Parabilis Medicines reports Q3 EPS (36c), consensus (38c)

Reports Q3 revenue $2.11M, consensus $375,000. “With each successive clinical update, we are building a stronger foundation for zolucatetide as a unique medicine with the potential to make a meaningful

9h agoPBLS EARNINGS

Parabilis Medicines initiated with a Buy at Canaccord

Canaccord initiated coverage of Parabilis Medicines (PBLS) with a Buy rating and $39 price target The firm says the company’s Helicon technology could greatly expand the list of “druggable” targets

3d agoPBLS

Parabilis Medicines initiated with a Buy at Canaccord

Canaccord initiated coverage of Parabilis Medicines (PBLS) with a Buy rating and $39 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

3d agoPBLS

PBLS: Buy Rating Reiterated as Zolucatetide’s Best-in-Class Potential and Clear Path to Approval Support Unchanged $45 Price Target

Parabilis Medicines, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tazeen Ahmad from Bank of America Securities maintained a Buy rating on the stock

2w agoPBLS

Parabilis Medicines announces safety, efficacy data for zolucatetide

Parabilis Medicines (PBLS) announced updated safety and efficacy data for zolucatetide, the first and only direct inhibitor of the beta-catenin:TCF interaction, in patients with desmoid tumors. The data were presented

2w agoPBLS

Parabilis Medicines initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Robert Burns initiated coverage of Parabilis Medicines (PBLS) with a Buy rating and $40 price target Parabilis is a clinical-stage biotechnology company pioneering innovative therapies against some

3w agoPBLS

Why Is Parabilis Medicines Stock (PBLS) Up 11% Today?

Parabilis Medicines stock was up on Monday following a clinical trial update and planned presentation.

3w agoPBLS

Parabilis Medicines rises 6.3%

Parabilis Medicines (PBLS) is up 6.3%, or $1.72 to $29.20. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks

1M agoPBLS

Parabilis Medicines falls -12.5%

Parabilis Medicines (PBLS) is down -12.5%, or -$5.22 to $36.51. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks

1M agoPBLS

Parabilis Medicines appoints Craig Tendler to board of directors

Parabilis Medicines (PBLS) announced the appointment of Craig Tendler to its board of directors. Tendler has served as a scientific advisor to Parabilis Medicines, a role he will continue alongside

2M agoPBLS

Parabilis Medicines reports Q2 EPS ($2.32), consensus (24c)

Reports Q2 revenue $148,000, consensus $16.67M. “This quarter marked meaningful progress toward our long-term vision as we continued advancing zolucatetide across multiple Wnt/beta-catenin-driven diseases, including toward planned registrational development in

2M agoPBLS EARNINGS

Parabilis Advances FOG-001 Trial in Tough Solid Tumors: What Investors Should Watch

Parabilis Medicines, Inc. ($PBLS) announced an update on their ongoing clinical study. Parabilis Medicines, Inc. is running a Phase 1/2 study called “A Phase 1/2 Study of FOG-001 in Participants

3M agoPBLS

Four new option listings on July 16th

New option listings for July 16th include Parabilis Medicines Inc (PBLS), GraniteShares 2x Short SK Hynix Daily ETF (SKDD), GraniteShares 2x Long SK Hynix Daily ETF (SKUU), and XMax Inc

3M agoPBLS XMAX

Analyst Initiates Buy on Parabilis, Citing First-in-Class Wnt Inhibitor Zolucatidine and Strong Cash Runway

Charles Zhu, an analyst from LifeSci Capital, has initiated a new Buy rating on Parabilis Medicines, Inc. (PBLS). Charles Zhu has given his Buy rating due to a combination of

4M agoPBLS

PBLS FAQ

What was Parabilis Medicines, Inc.’s price range in the past 12 months?

Parabilis Medicines, Inc. lowest stock price was $22.66 and its highest was $42.49 in the past 12 months.

What is Parabilis Medicines, Inc.’s market cap?

Parabilis Medicines, Inc.’s market cap is $3.71B.

When is Parabilis Medicines, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Parabilis Medicines, Inc.’s earnings last quarter?

Parabilis Medicines, Inc. released its earnings results on Nov 12, 2026. The company reported -$0.36 earnings per share for the quarter.

Is Parabilis Medicines, Inc. overvalued?

According to Wall Street analysts Parabilis Medicines, Inc.’s price is currently Undervalued.

Does Parabilis Medicines, Inc. pay dividends?

Parabilis Medicines, Inc. does not currently pay dividends.

What is Parabilis Medicines, Inc.’s EPS estimate?

Parabilis Medicines, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Parabilis Medicines, Inc. have?

Parabilis Medicines, Inc. has 121,952,030 shares outstanding.

What happened to Parabilis Medicines, Inc.’s price movement after its last earnings report?

Parabilis Medicines, Inc. reported an EPS of -$0.36 in its last earnings report. Following the earnings report the stock price went down -4.651%.

Which hedge fund is a major shareholder of Parabilis Medicines, Inc.?

Hedge funds hold Parabilis Medicines, Inc. shares: the largest hedge-fund position in Parabilis Medicines, Inc. is 70,145,302 shares.

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Parabilis Medicines, Inc. Stock Smart Score

Outperform

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description